Holen Sie sich die Stockscreener-App
1.76
3.96%
0.12
Handel nachbörslich:
1.74
-0.02
-1.14%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.7
24-Stunden-Volumen:
1.92M
Relative Volume:
1.33
Marktkapitalisierung:
$118.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-122.44M
KGV:
-0.7808
EPS:
-2.254
Netto-Cashflow:
$-103.79M
1W Leistung:
+11.44%
1M Leistung:
-78.66%
6M Leistung:
-79.33%
1J Leistung:
-59.79%
1-Tages-Spanne:
$1.635
$1.79
1-Wochen-Bereich:
$1.53
$1.76
52-Wochen-Spanne:
$1.40
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Firmenname
Engene Therapeutics Inc
Sektor
Branche
Telefon
(514) 332-4888
Adresse
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
1.77 | 109.86M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | WBB Securities | Buy |
| 2026-01-30 | Eingeleitet | Jefferies | Buy |
| 2025-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-14 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-27 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-03-28 | Eingeleitet | UBS | Buy |
| 2024-03-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Engene Therapeutics Inc Aktie (ENGN) Neueste Nachrichten
EnGene bladder cancer data shows promise, but durability questions remain - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc.ENGN - Sahm
Dow Dips 350 Points; US Foods Posts Downbeat Earnings - Sahm
Law firm probes enGene Therapeutics over stock plunge after disappointing cancer trial results - Pluang
Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc.ENGN - FinancialContent
EnGene Therapeutics (ENGN) price target decreased by 64.55% to 8.72 - MSN
enGene (ENGN) filing: Cormorant and Bihua Chen report 0 shares - Stock Titan
BML Investment Partners reports 9.95% stake in enGene Holdings (ENGN) - Stock Titan
ENGN SEC FilingsenGene Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
UBS Adjusts EnGene Price Target to $2 From $9, Maintains Neutral Rating - Moomoo
UBS Maintains EnGene Therapeutics(ENGN.US) With Hold Rating, Cuts Target Price to $2 - Moomoo
Why is enGene Therapeutics stock falling Friday? - MSN
BML Investment Partners discloses 7.8% stake in enGene (ENGN) on 05/08/2026 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations - Yahoo Finance
ENGN Plunges As enGene Faces LEGEND Trial Setback And Legal Probe - timothysykes.com
enGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBCSlideshow (NASDAQ:ENGN) 2026-05-09 - Seeking Alpha
Why Is enGene Therapeutics Stock Falling Friday? - Sahm
enGene Stock Plunges As LEGEND Trial Downgrades Mount - timothysykes.com
enGene Therapeutics Inc.Common Stock (ENGN) Stock Price, News, Quote & History - FinancialContent
enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data UpdateWhat's Changed - simplywall.st
Guggenheim downgrades EnGene Therapeutics (ENGN) - MSN
enGene Holdings (ENGN) Gets a Buy from H.C. Wainwright - The Globe and Mail
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain - sharewise.com
enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed? - Yahoo Finance
[ARS] enGene Therapeutics Inc. SEC Filing - Stock Titan
enGene Therapeutics (NASDAQ: ENGN) details 2026 virtual shareholder meeting - Stock Titan
ENGN Stock Collapses As Street Slashes Targets After Trial Shock - StocksToTrade
Guggenheim Downgrades EnGene Holdings to Neutral From Buy - Moomoo
EnGene cancer sales forecast cut after new data widen gap to J&J - Fierce Biotech
A Quick Look at Today's Ratings for EnGene Therapeutics(ENGN.US), With a Forecast Between $2 to $6 - Moomoo
Citizens Downgrades EnGene to Market Perform From Market Outperform - Moomoo
Oppenheimer Downgrades EnGene Holdings to Market Perform From Outperform - Moomoo
Morgan Stanley Downgrades EnGene Holdings to Equalweight From Overweight - Moomoo
Engene stock rating cut to Perform by Oppenheimer on trial data By Investing.com - Investing.com South Africa
Piper Sandler cuts Engene Holdings stock rating on trial concerns By Investing.com - Investing.com South Africa
Piper Sandler cuts Engene Holdings stock rating on trial concerns - Investing.com UK
Engene stock rating cut to Perform by Oppenheimer on trial data - Investing.com Nigeria
Citizens downgrades Engene Holdings stock rating on weaker trial data By Investing.com - Investing.com UK
Guggenheim downgrades Engene stock rating on weaker trial data By Investing.com - Investing.com Nigeria
Raymond James downgrades Engene Holdings stock rating on trial results By Investing.com - Investing.com UK
enGene reports 54% response rate in bladder cancer trial By Investing.com - Investing.com South Africa
Finanzdaten der Engene Therapeutics Inc-Aktie (ENGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):